ACTG 372:PROLONGATION OF VIROLOGIC SUCCESS & OPTIONS FOR FAILURE IN H

ACTG 372：延长病毒学成功

• 批准号: 6264445
• 负责人: ROBERT KALAYJIAN
• 金额: $ 1.92万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264445
• 关键词: AIDS therapy; HIV infections; clinical research; combination chemotherapy; human subject; human therapy evaluation; lamivudine; stavudine; zidovudine

CORE LAB ONLY - SAMPLE PROCESSING. This trial is a study with parallel questions to be evaluated. The overarching rational for ACTG 372 is to explore relevant questions while examining new treatment options for enrollees who have been receiving ZDV (or d4T) +3TC+IDV and are currently exhibiting a range of virologic responses. By dividing the study into the corresponding, non-sequential cohorts, different approaches to evaluating virologic success and virologic failure can be explored while maintaining long-term follow-up of subjects. Providing rollover options for all subjects on a particular regimen in an ACTG trial, irrespective of response, is a desirable goal as new approaches to managing response and failure can be pursued in parallel and in an efficient manner.

仅限核心实验室-样品处理。这项试验是一项有平行问题待评估的研究。ACTG 372的主要目的是探索相关问题，同时为接受ZDV（或d4T） +3TC+IDV治疗且目前表现出一系列病毒学应答的入组者研究新的治疗方案。通过将研究分成相应的非顺序队列，可以在对受试者进行长期随访的同时，探索评估病毒学成功和失败的不同方法。为ACTG试验中某一特定方案的所有受试者提供翻转选择，而不管反应如何，这是一个理想的目标，因为管理反应和失败的新方法可以并行和有效地进行。